标题
Fabry Disease Therapy: State-of-the-Art and Current Challenges
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 1, Pages 206
出版商
MDPI AG
发表日期
2020-12-28
DOI
10.3390/ijms22010206
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Developments in the treatment of Fabry disease
- (2020) Sanne J. Veen et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)
- (2020) Malte Lenders et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- New drugs for the treatment of Anderson–Fabry disease
- (2020) Sandro Feriozzi et al. JOURNAL OF NEPHROLOGY
- Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
- (2020) Eleonora Riccio et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study
- (2020) Ulla Feldt-Rasmussen et al. MOLECULAR GENETICS AND METABOLISM
- In Vitro and In Vivo Amenability to Migalastat in Fabry Disease
- (2020) Malte Lenders et al. Molecular Therapy-Methods & Clinical Development
- Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy
- (2019) Frank DeRosa et al. MOLECULAR THERAPY
- Once every 4 weeks - 2 mg/kg of pegunigalsidase alfa for treating Fabry disease Preliminary results of a phase 3 study
- (2019) Myrl D. Holida et al. MOLECULAR GENETICS AND METABOLISM
- Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa
- (2019) Ales Linhart et al. MOLECULAR GENETICS AND METABOLISM
- Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1/2 clinical trial
- (2019) Raphael Schiffmann et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease
- (2019) Julia B. Hennermann et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
- (2019) Dominique P. Germain et al. GENETICS IN MEDICINE
- Migalastat: A Review in Fabry Disease
- (2019) Emma H. McCafferty et al. DRUGS
- Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates
- (2019) Xuling Zhu et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy
- (2019) Malte Lenders et al. JOURNAL OF MEDICAL GENETICS
- Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype
- (2019) Olga Azevedo et al. MOLECULAR GENETICS AND METABOLISM
- Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
- (2018) Jonas Müntze et al. EUROPEAN HEART JOURNAL
- Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
- (2018) Maarten Arends et al. JOURNAL OF MEDICAL GENETICS
- Fabry disease revisited: Management and treatment recommendations for adult patients
- (2018) Alberto Ortiz et al. MOLECULAR GENETICS AND METABOLISM
- Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial
- (2018) Raphael Schiffmann et al. Orphanet Journal of Rare Diseases
- Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease
- (2018) Malte Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Development and clinical consequences of white matter lesions in Fabry disease: a systematic review
- (2018) Simon Körver et al. MOLECULAR GENETICS AND METABOLISM
- Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
- (2018) Jonas Müntze et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease
- (2018) Malte Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment
- (2018) S.J. van der Veen et al. MOLECULAR GENETICS AND METABOLISM
- Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
- (2017) Michael Mauer et al. JOURNAL OF MEDICAL GENETICS
- Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease
- (2017) Maarten Arends et al. MOLECULAR GENETICS AND METABOLISM
- The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
- (2016) Elfrida R. Benjamin et al. GENETICS IN MEDICINE
- Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes
- (2016) Ja Hye Kim et al. JOURNAL OF HUMAN GENETICS
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
- (2016) Derralynn A Hughes et al. JOURNAL OF MEDICAL GENETICS
- Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
- (2016) Maarten Arends et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry
- (2016) Robert J. Hopkin et al. MOLECULAR GENETICS AND METABOLISM
- Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients
- (2016) Rannveig Skrunes et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
- (2016) Dominique P. Germain et al. NEW ENGLAND JOURNAL OF MEDICINE
- One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease
- (2016) Behzad Najafian et al. PLoS One
- A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease
- (2015) Raphael Schiffmann et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
- (2015) Jin-Song Shen et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
- (2015) Dominique P Germain et al. JOURNAL OF MEDICAL GENETICS
- Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up
- (2015) M. Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
- (2015) M. Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease
- (2015) Tali Kizhner et al. MOLECULAR GENETICS AND METABOLISM
- Unknown
- (2015) Karen Ashe et al. MOLECULAR MEDICINE
- Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
- (2015) Christoph Kampmann et al. Orphanet Journal of Rare Diseases
- Quality of life in patients with Fabry disease: a systematic review of the literature
- (2015) Maarten Arends et al. Orphanet Journal of Rare Diseases
- Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
- (2015) Lubor Goláň et al. Drug Design Development and Therapy
- Enzyme Replacement Therapy Stabilized White Matter Lesion Progression in Fabry Disease
- (2014) Andreas Fellgiebel et al. CEREBROVASCULAR DISEASES
- Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch
- (2014) F. Weidemann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Outcomes of patients treated through the Canadian Fabry disease initiative
- (2014) S.M. Sirrs et al. MOLECULAR GENETICS AND METABOLISM
- Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry
- (2013) Dominique P. Germain et al. GENETICS IN MEDICINE
- A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease
- (2013) D.A. Hughes et al. MOLECULAR GENETICS AND METABOLISM
- The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry Nephropathy
- (2012) S. Feriozzi et al. Clinical Journal of the American Society of Nephrology
- Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease
- (2012) D. Marchesan et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Enzyme replacement therapy improves cardiac features and severity of Fabry disease
- (2012) Manish Motwani et al. MOLECULAR GENETICS AND METABOLISM
- A revised home treatment algorithm for Fabry disease: Influence of antibody formation
- (2012) B.E. Smid et al. MOLECULAR GENETICS AND METABOLISM
- Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
- (2012) Saskia M. Rombach et al. PLoS One
- Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS—the Fabry Outcome Survey
- (2011) Derralynn A. Hughes et al. MOLECULAR GENETICS AND METABOLISM
- Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
- (2011) D. G. Warnock et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
- (2011) Bouwien E Smid et al. Orphanet Journal of Rare Diseases
- Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
- (2011) Thaneas Prabakaran et al. PLoS One
- Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy
- (2010) Mariëlle J. van Breemen et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
- (2010) Torquil Watt et al. GENETICS IN MEDICINE
- Fabry disease
- (2010) Dominique P Germain Orphanet Journal of Rare Diseases
- Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy
- (2009) Frank Weidemann et al. CIRCULATION
- Cardiac Microvascular Pathology in Fabry Disease
- (2009) Beth L. Thurberg et al. CIRCULATION
- Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease
- (2009) Jean-Claude Lubanda et al. GENETICS IN MEDICINE
- Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry
- (2009) Stephen Waldek et al. GENETICS IN MEDICINE
- A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease
- (2009) Catharina Whybra et al. GENETICS IN MEDICINE
- Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey
- (2009) A Mehta et al. JOURNAL OF MEDICAL GENETICS
- The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease
- (2009) Richie Khanna et al. MOLECULAR THERAPY
- A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease
- (2008) Bernard Bénichou et al. MOLECULAR GENETICS AND METABOLISM
- An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia
- (2008) Riki Okeda et al. NEUROPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started